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HIGHLIGHTS 
 Use of cannabis or its main active ingredient Δ9-THC is associated with psychosis 
 Evidence of the effects of Δ9-THC or cannabis on the dopamine system in man is equivocal 
 Chronic cannabis use reduces glutamate or its metabolites levels in human brain 
 Δ9-THC alters glutamate signalling in animal brain 
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ABSTRACT 
 
Use of cannabis or delta-9-tetrahydrocannabinol (Δ9-THC), its main psychoactive 
ingredient, is associated with psychotic symptoms or disorder. However, the neurochemical 
mechanism that may underlie this psychotomimetic effect is poorly understood. Although 
dopaminergic dysfunction is generally recognized as the final common pathway in psychosis, 
evidence of the effects of Δ9-THC or cannabis use on dopaminergic measures in the brain is 
equivocal. In fact, it is thought that cannabis or Δ9-THC may not act on dopamine firing directly 
but indirectly by altering glutamate neurotransmission. Here we systematically review all studies 
examining acute and chronic effects of cannabis or Δ9-THC on glutamate signalling in both animals 
and man. Limited research carried out in humans tends to support the evidence that chronic 
cannabis use reduces levels of glutamate-derived metabolites in both cortical and subcortical brain 
areas. Research in animals tends to consistently suggest that Δ9-THC depresses glutamate synaptic 
transmission via CB1 receptor activation, affecting glutamate release, inhibiting receptors and 
transporters function, reducing enzyme activity, and disrupting glutamate synaptic plasticity after 
prolonged exposure.  
 
Keywords: Cannabis; Delta-9-tetrahydrocannabinol; Glutamate signalling; Glutamatergic synaptic 
transmission; Cannabinoid receptor type 1 
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1. INTRODUCTION 
Convergent and replicated findings suggest that use of cannabis or delta-9-
tetrahydrocannabinol (Δ9-THC), the main psychoactive ingredient in cannabis, is associated with 
psychotic symptoms (Bhattacharyya et al., 2012a; Bhattacharyya et al., 2009a) or disorder (Moore 
et al., 2007; Murray et al., 2007), and its relapse (Colizzi et al., in press; Patel et al., in press; 
Schoeler et al., in press), consistent with independent evidence of endocannabinoid abnormalities in 
psychosis (summarized in Appiah-Kusi et al., 2016). However, the neurochemical abnormality that 
may underlie this psychotomimetic effect is poorly understood. Whilst evidence for the 
involvement of presynaptic dopamine dysfunction in psychosis is compelling (Howes et al., 2015), 
data from candidate gene-interaction studies seem to suggest vulnerability to the psychotomimetic 
and cognitive effects of cannabis use involving genes that control dopamine signalling particularly 
postsynaptically (Bhattacharyya et al., 2012a; Bhattacharyya et al., 2014; Colizzi et al., 2015a; 
Colizzi et al., 2015b). Also, evidence from human studies of the effect of cannabis use on acute 
striatal dopamine release or chronic dopamine receptor status is equivocal (summarized in Sami et 
al., 2015), though studies using functional neuroimaging techniques provide indirect evidence of the 
acute effect of Δ9-THC on dopaminergic regions such as striatum or midbrain across a range of 
different cognitive tasks (Bhattacharyya et al., 2009a; Bhattacharyya et al, 2009b; Bhattacharyya et 
al., 2012a; Bhattacharyya et al., 2012b; Bhattacharyya et al., 2015a).  
Δ9-THC is a cannabinoid receptor type 1 (CB1) and 2 (CB2) partial agonist and the strength 
of its effects that are mediated by CB1 or CB2 receptors can be affected by endogenous 
cannabinoids and by the density and signalling efficiency of these receptors (Pertwee, 2008; Colizzi 
et al., 2015c). For example, if CB1 and CB2 are down-regulated or being targeted by endogeneous 
agonists, Δ9-THC may act as an antagonist whereas it will exert its partial agonist effect if receptors 
are up-regulated or endogeneous agonist levels are low. Interestingly, evidence is emerging that 
continued cannabis use may be associated with CB1 receptor alteration in the brain (Ceccarini et al., 
5 
 
2015; Hirvonen et al., 2012).  Evidence has also emerged suggesting that Δ9-THC affects dopamine 
release indirectly via a CB1-dependent inhibition of glutamate release onto gamma-aminobutyric 
acid (GABA) neurons in the nucleus accumbens and the ventral tegmental area (Pertwee, 2008). 
This model might explain the modest striatal dopamine release observed in Δ9-THC challenge 
studies (reviewed in Sami et al., 2015), offering a possible key to the understanding of the biology 
underlying cannabis-induced psychosis. 
This effect of Δ9-THC on glutamate signalling represents a promising neurochemical 
mechanism that may underlie the psychotomimetic effect of this cannabinoid. Although only a few 
studies have investigated the effects of cannabis exposure on glutamate signalling in humans 
(Chang et al., 2006; Muetzel et al., 2013; Prescot et al., 2011; Prescot et al., 2013; Sung et al., 
2013), a large body of evidence has accumulated from animal studies on the effect of exogenous 
cannabinoids on different glutamate-related outcome measures. The purpose of this review is to 
bring together and discuss all available data generated by human and animal studies that have 
investigated the acute and chronic effects of cannabis and Δ9-THC on the glutamatergic 
neurotransmitter system by carrying out a systematic literature search for all such data. 
 
1.1. Objectives  
Our main objective was to carry out a systematic review of all available literature 
concerning effects of cannabis and Δ9-THC on the glutamate system in humans as well as animal 
models. We aimed to review all interventional and observational studies, employing both 
retrospective and prospective methodologies with any reported neurochemical outcomes related to 
the glutamate system after exposure to cannabis or Δ9-THC.  
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2. EXPERIMENTAL PROCEDURES 
2.1. Inclusion/exclusion criteria 
Inclusion criteria for studies were: (1) human or animal studies, (2) studies investigating the 
acute and/or long-term effects of cannabis use/administration or Δ9-THC 
administration/application, (3) studies measuring molecular markers related to glutamate 
neurotransmission, including (a) glutamate metabolites, (b) synaptic transmission, (c) enzyme 
activity, (d) neurotransmitter release, (e) neurotransmitter uptake, (f) transporters, (g) receptors, (h) 
brain neurotransmitter levels. Exclusion criteria were (1) studies where cannabis or Δ9-THC were 
not the intervention or exposure of interest (i.e. studies including only synthetic cannabinoid 
agonists/antagonists) and (2) studies in which the neurochemical outcomes were not directly 
reported upon.  
 
2.2. Search strategy 
A final search was undertaken on the 29
th
 of October 2015. The search terms used were: 
(cannabis or Δ9-THC or marijuana or marihuana or tetrahydrocannabinol or dronabinol) and (glu* 
or glutamate(s) or glutamine or glutamic acid). This search was undertaken in Medline, EMBASE, 
and PsychInfo using the OvidSP platform. All studies published in any language and indexed in the 
above databases were included. Reference lists from all identified relevant studies, reviews and 
conference abstracts were screened for any additional relevant studies.  
 
2.3. Data extraction 
Demographic and methodological variables and outcome data for studies identified were 
extracted into a spreadsheet. Primary outcomes of interest were neurochemical markers pertaining 
to the glutamatergic system. These were compared within interventional/exposed cohorts and/or 
between exposed and non-exposed control groups. Studies were grouped based on the investigated 
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population (humans or animal models); animal studies were further grouped depending on the Δ9-
THC challenge strategy [application (in vitro studies) or administration (in vivo studies)] and the 
animal model stage of development (embryonal or postnatal).  
 
2.4. Risk of bias 
Risk of bias and quality assessment of the methodologically heterogeneous group of studies 
(Table 1) reviewed here required a suitably inclusive and flexible approach. For this purpose, an 
adapted set of criteria suggested by the Agency for Healthcare Research and Quality (AHRQ) 
guidance (West et al., 2002), amended as appropriate for observational studies in humans was used 
(Table 2a). Risk of systematic bias across human studies was further identified by assessing all 
papers for possible confounding factors such as mental health comorbidity, tobacco, alcohol, and 
other substance use in cannabis users (Table 2b). Also, in order to evaluate potential factors that 
may explain similarities/differences in results across animal studies, information was derived 
regarding study characteristics, such as animal model (e.g. mouse or rat), stage of development (i.e. 
embryonal or postnatal), sex, weight, and dosage of cannabinoids used (Table 3-6).    
 
3. RESULTS 
3.1. Study selection 
In total 268 records were identified. All abstracts of the records were screened against the 
inclusion and exclusion criteria. A final list of 41 studies (5 human; 36 animal) was identified for 
systematic analysis in this review (Table 1). Cumulatively, the included studies investigated 
different aspects of the glutamate signalling pathway (Table 1) in response to cannabis or Δ9-THC 
exposure. These include (1) in vivo glutamate-related metabolites in chronic human cannabis users 
(Table 2a); (2) synaptic transmission, enzyme activity, neurotransmitter release and uptake, and 
extracellular levels in animal models after in vitro application of Δ9-THC and other cannabinoids 
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(Table 3); (3) enzyme activity, neurotransmitter release and uptake, extracellular levels, 
transporters, and receptors function in animal models after in vivo Δ9-THC embryonal exposure 
(Table 4); (4) synaptic transmission, enzyme activity, neurotransmitter release, intracerebral levels, 
and receptor function in animal models after in vivo Δ9-THC postnatal exposure (Table 5); (5) 
synaptic transmission, transporters, and receptor function in animal models after in vivo Δ9-THC 
postnatal exposure, followed by additional in vitro Δ9-THC exposure (Table 6). Further 
information on methodological quality of studies carried out in humans is reported in Table 2b. A 
brief synopsis of the key findings is reported below. 
 
3.2. In vivo changes in levels of glutamate-related metabolites in response to 
cannabis use in humans  
Five studies have addressed this area in humans, all using in vivo Proton Magnetic 
Resonance Spectroscopy (1H-MRS; Table 2a, Table 2b). Three studies investigated metabolites in 
the cerebral cortex, with particular attention to the anterior cingulate cortex (Prescot et al., 2011; 
Prescot et al., 2013; Sung et al., 2013), while the other two studies investigated metabolites in 
subcortical areas, in particular basal ganglia (Chang et al., 2006; Muetzel et al., 2013). One study 
additionally investigated metabolites in the frontal white matter (Chang et al., 2006). 
Chang and colleagues (2006) conducted the first study in humans investigating brain 
glutamate levels in healthy individuals with a chronic history of cannabis use. They found that 
subjects who have used cannabis almost daily for at least one year (n=24) show a 9.5% reduction 
in their basal ganglia glutamate metabolite levels compared to cannabis-naive subjects (n=30). This 
evidence was even more robust when they also considered 42 individuals with Human 
Immunodeficiency Virus (HIV) infection, 21 of them with a history of chronic cannabis use. This 
second analysis (n=96) indicated that chronic cannabis users with and without comorbid HIV have 
a 12-13% decrease in their glutamate metabolite levels. HIV infection alone did not have a 
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significant effect on basal ganglia glutamate levels. The same model of analysis was used in order 
to investigate the effects of chronic cannabis use on glutamate metabolite levels in the frontal white 
matter. While an initial analysis failed to show a significant main effect of chronic cannabis use on 
glutamate metabolite levels (n=54, 24 cannabis users and 30 cannabis naive subjects), a second 
analysis including the 42 HIV positive individuals (n=96, 24 healthy cannabis users, 21 HIV 
individuals, 21 HIV cannabis users, and 30 cannabis naive subjects) revealed that healthy cannabis 
users have lower glutamate levels compared to cannabis naive subjects.  
In a similarly sized study (n=53), Muetzel and colleagues (2013) found that glutamate 
metabolite levels in the dorsal striatum are non-significantly decreased in chronic cannabis users 
(n=27) compared to controls (n=26). However, their study suggested a group by sex interaction, 
with female cannabis users having a significant (12.5%) decrease in their glutamate metabolite 
levels.  
In two different studies (2011, n=34; 2013, n=29) Prescot and colleagues found that, 
compared to cannabis-naive subjects (n=17 and n=16 respectively), chronic cannabis users (n=17 
and n=13 respectively) exhibited a significant (14-15%) reduction in glutamate metabolite levels in 
the anterior cingulate cortex. These findings were not replicated by Sung et al. (2013, n=27) using 
a similar region of interest (ROI) approach. However, this last study investigated a modestly sized 
sample of cannabis users with comorbid methamphetamine use (n=8). Methamphetamine alone 
(n=9) also did not show any main effect on glutamate metabolites levels in the anterior cingulate 
cortex.  
 
 
 
3.2.1. Risk of systematic bias across human studies 
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While generally well-designed, the results mentioned above (Section 3.2.) need to be 
considered in light of certain limitations. All of the studies investigated effects of chronic cannabis 
use. As long-term exposure to Δ9-THC, the psychoactive ingredient of cannabis, has been reported 
to block synaptic plasticity and reduce the sensitivity of glutamatergic synapses to cannabinoids in 
animal models (Hoffman et al., 2003), acute Δ9-THC challenge studies are needed to better 
elucidate the effects of cannabis on baseline glutamate responses. Moreover, across the studies that 
investigated chronic cannabis use, individuals differed in terms of their last cannabis use. While 
one study investigated cannabis users who were abstinent for at least 12 hours before scanning 
(Muetzel et al., 2013), another reported a wide range of abstinence, from no abstinence to 20 years 
(Chang et al., 2006), and a third reported that 54% of subjects had used cannabis within 24 hours 
before scanning (Prescot et al., 2013). No information on period of abstinence was available for the 
other two studies. These differences could be associated with considerable inter-individual 
variation in cannabis bio-availability in the brain, which may potentially affect spectroscopic 
measures. Also, the outcome measure was not the same for all studies, involving glutamate + 
glutamine metabolite measurement for two studies (Muetzel et al., 2013; Sung et al., 2013) but 
only glutamate metabolite measurement for the others (Chang et al., 2006; Prescot et al., 2011; 
Prescot et al., 2013). In two of the studies (Prescot et al., 2011; Prescot et al., 2013) metabolite 
levels were corrected for water while correction was carried out for cerebrospinal fluid or total 
creatine or phosphocreatine + creatine in the other studies (Chang et al., 2006; Muetzel et al., 2013; 
Sung et al., 2013), making comparisons difficult across studies. Moreover, three studies also 
included participants with a mental health problem (Muetzel et al., 2013; Prescot et al., 2011; 
Prescot et al., 2013), and in two of them this involved participants undergoing treatment for 
depression (Prescot et al., 2011; 2013) which was not accounted for in analyses in one of these 
studies (Prescot et al., 2011). Finally, while substance use represented an exclusion criterion in all 
the studies, alcohol use was an exclusion criterion only in one study (Chang et al., 2006); similarly, 
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tobacco use was an exclusion criterion only in one study and only for cannabis users (Muetzel et 
al., 2013). All the other studies registered an increase in tobacco and alcohol use (or 
abuse/dependence) in cannabis users compared to controls and in one report this information was 
not provided or corrected for (Prescot et al., 2011).  
 
3.3. Glutamate-related outcome measures in response to cannabis/Δ9-THC 
application/administration in animal models  
Thirty-six studies addressed this area in animal models, employing different strategies: 
embryonal/postnatal in vitro Δ9-THC exposure (Table 3, 7 studies), embryonal (Table 4, 7 studies) 
and postnatal (Table 5, 17 studies) in vivo Δ9-THC exposure; and postnatal in vivo Δ9-THC 
exposure followed by in vitro Δ9-THC (Table 6, 5 studies). 
 
3.3.1. Animal studies of glutamatergic effects of in vitro Δ9-THC exposure 
The first in vitro study was conducted by Shen and Thayer (1999), who explored 
hippocampal glutamatergic synaptic transmission after application of Δ9-THC in embryonal rat 
cells. Additional information was obtained by the use of WIN55,212-2 and SR141716A, a potent 
CB1 receptor agonist and a CB1-selective antagonist respectively. Results from this study suggest 
that Δ9-THC can reduce, but not block, excitatory neurotransmission, by acting presynaptically in 
the glutamatergic system. In particular, Δ9-THC exhibited high potency, but rather modest efficacy 
compared to the WIN55,212-2; also its action was prevented by SR141716A; finally, it appeared 
that Δ9-THC has both agonist and antagonist properties, being able to partially reverse the 
WIN55,212-2-induced full block of the excitatory neurotransmission. A second study (Brown et 
al., 2003) indicated that Δ9-THC reduces both the release and uptake of glutamate in rat striatal 
slices in a dose-dependent manner that is mediated by CB1 receptor activation; these effects were 
prevented in slices pre-treated with selective CB1 receptor antagonists but only partially reversed 
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by post-treatment. It was also found in this study that both activation of CB1 receptors and 
inhibition of glutamate uptake reduce corticostriatal synaptic transmission in a mutually inhibitory 
manner and that both forms of depression are dependent on metabotropic glutamate receptor 
(mGluR) activation (Brown et al., 2003). Straiker and Mackie (2005) were able to show temporary 
and long-lasting effects of different cannabinoids resulting in CB receptor-mediated reduction in 
glutamate transmission in mice. Authors confirmed the involvement of the CB1 receptor activation 
(Brown et al., 2003; Shen and Thayer, 1999) in the reduction of glutamate neurotransmission as all 
these effects were absent in CB1 knockout (KO) mice and/or reversed by the antagonist 
SR141716A, and that Δ9-THC antagonizes CB1 receptors in the short term (Shen and Thayer, 
1999), but desensitizes them in the long term. However, in their studies Δ9-THC did not inhibit 
glutamate neurotransmission, even when using higher dosages compared to previous studies (Shen 
and Thayer, 1999; Brown et al., 2003). A more recent study (Hoffman et al., 2010) identified a 
likely cause of this discrepancy, showing different sensitivities among rodent species (rat vs 
mouse) to Δ9-THC at excitatory and inhibitory axon terminals in the hippocampus. Consistently, 
Δ9-THC was shown to induce depression of glutamate neurotransmission in rats but not in mice, as 
previously reported (Brown et al., 2003; Shen and Thayer, 1999; Straiker and Mackie, 2005). 
Interestingly, this difference seemed to be attributable to species differences in brain adenosine 
systems. Finally, Irie and colleagues (2015) suggested that Δ9-THC inhibits glutamatergic synaptic 
transmission also in the cerebellum by the same molecular mechanism; in particular, Δ9-THC 
seems to suppress the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 
receptors. Again, Δ9-THC was a less potent inhibitor than a potent synthetic CB1 receptor agonist 
(Irie et al., 2015). In contrast to this evidence suggesting a Δ9-THC-induced reduction in glutamate 
synaptic transmission, Tomasini et al. (2002) found that in vitro Δ9-THC application increases 
glutamate release and extracellular levels, suggesting an increase in cortical glutamatergic 
neurotransmission can be induced by CB1 receptor activation. 
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Only one in vitro study focused on glutamate enzyme activity (Monnet-Tschudi et al., 
2008), and this showed that in aggregating brain cell cultures Δ9-THC reduces the activity both of 
glutamic acid decarboxylase (GAD), which catalyzes the decarboxylation of glutamate to GABA, 
and of glutamine synthetase (GS), which catalyzes the condensation of glutamate (Glu) and 
ammonia to form glutamine (Gln). Interestingly, use of both a CB1 receptor-selective agonist and a 
CB2 receptor-selective agonist in this study yielded data suggesting that the effects of Δ9-THC on 
GAD and GS activity are more likely caused by CB2 than CB1 receptor activation. 
 
3.3.2. Animal studies of glutamatergic effects of embryonal in vivo Δ9-THC exposure  
All these studies investigated the effect of prenatal exposure to Δ9-THC on glutamate 
signalling, using overlapping methodology (mode of administration, period of exposure, and 
dosage of Δ9-THC), even if investigating different brain regions of interest. Apart from one study 
(Castaldo et al., 2007), which confined Δ9-THC exposure to the embryonal period, all others 
prolonged it to postnatal age.  
Castaldo and colleagues (2007) showed that adolescent rats which were exposed to Δ9-
THC during gestation had a reduction in their basal extracellular glutamate levels. Prenatal 
exposure to WIN55,212-2 induced the same alteration. By studying the effects of this CB1 agonist 
on glutamate uptake and transporters, it was found that a possible explanation accounting for CB1-
mediated glutamate outflow reduction may be an increase of glutamate uptake as a consequence of 
enhanced expression of the glutamate transporter 1 (GLT1) and excitatory amino acid carrier 
(EAAC1) protein. 
Three studies assessed the activity of different enzymes in the glutamate metabolic pathway 
after embryonal exposure to Δ9-THC. Garcia-Gil et al. (1999) found that Δ9-THC does not 
produce any changes in glutamic acid decarboxylase (GAD) activity across several rat brain areas. 
On the contrary, glutamine synthetase (GS) activity has been reported to be reduced in the 
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cerebellar cortex of rats exposed to Δ9-THC; interestingly, GS expression increased progressively 
after Δ9-THC withdrawal, but did not reach control levels in male rats even two months after 
withdrawal (Suarez et al., 2002). Finally, Campolongo et al. (2007) showed that early exposure 
to Δ9-THC might interfere with the rigidly ordered temporal sequence of events that occur during 
the ontogeny of the central nervous system, leading to long-lasting neurodevelopmental alterations, 
including prefrontal enzyme activity. In addition, this study both confirmed a reduction in basal 
extracellular glutamate levels (Castaldo et al., 2007) and showed an alteration in glutamate 
receptors in offspring exposed to Δ9-THC during gestation.  
Suarez et al. (2004a; 2004b) carried out two studies on the long-term effects of Δ9-THC 
exposure during development in rat cerebellum, indicating down-regulation of both glial 
(glutamate aspartate transporter, GLAST) and neuronal (excitatory amino acid carrier, EAAC1) 
glutamate transporter expression, and decreased expression of glutamate receptors 1 and 2/3 
(GluR1; GluR2/3). Collectively, these findings suggest an abnormal maturation of the 
glutamatergic neuron-glia circuitry leading to a long-lasting inhibition of glutamatergic 
neurotransmission.   
 Finally, Castaldo and colleagues (2010) confirmed previous findings by Brown et al., 
(2003) or by Suarez et al. (2004b), that glutamate release at synapses is inhibited by prenatal 
exposure to Δ9-THC (Brown et al., 2003) with reduction in the functional activity and expression 
of glutamate transporters (Suarez et al., 2004b) (glutamate transporter 1, GLT1; GLAST). 
However, Castaldo et al. (2010) demonstrated that further in vitro application of low Δ9-THC 
concentrations enhanced hippocampal glutamate release in the hippocampus of vehicle-exposed 
rats, while this effect was selectively lost in rats exposed to Δ9-THC during gestation, suggesting 
that alteration in glutamatergic neurotransmission could partially depend on the loss of a similar 
control by endocannabinoids.  
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3.3.3. Animal studies of effect of postnatal in vivo Δ9-THC exposure on glutamate 
Out of 17 studies carried out to investigate the effects of postnatal in vivo Δ9-THC 
administration on glutamate, 4 investigated glutamatergic synaptic transmission, 3 of them also 
providing information on glutamate receptors, while one also assessed neurotransmitter release and 
intracerebral levels. The remaining 13 studies assessed a single outcome: glutamate receptors 
(n=3), release (n=2), intracerebral levels (n=4), and enzyme activity (n=4). 
Fan and colleagues (2010) confirmed that Δ9-THC impairs hippocampal glutamate synaptic 
transmission even when administered postnatally. Once again, Δ9-THC-induced depression of 
glutamatergic synaptic transmission seemed to require CB1 receptor activation, since it was 
prevented by administration of the CB1 receptor antagonist SR141716A, and absent in CB1 KO 
mice. Also, this alteration was associated with Δ9-THC-induced down-regulation of the expression 
of glutamate receptors and increases in glutamate release and intracellular levels. Good and Lupica 
(2010) obtained evidence that GluR2-lacking α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptors could be selectively increased at subcortical pedunculopontine nucleus 
(PPN) synapses following postnatal exposure to Δ9-THC, and that this can provide a substrate to 
permit long-term depression (LTD) in glutamatergic synaptic transmission. These effects were 
prevented by in vivo pretreatment with the cannabinoid CB1 receptor antagonist AM251, in line 
with other studies (Fan et al., 2010; Han et al., 2012; Liu et al., 2010). Another study explored Δ9-
THC effects on the Ventral Tegmental Area (VTA), and showed that chronic exposure to Δ9-THC 
activates VTA CB1 receptors to induce transient depression of neurotransmission at VTA 
Glutamate-Dopamine (Glu-DA) synapses through the activation of N-methyl-D-aspartate (NMDA) 
receptors (Liu et al., 2010). This finding was confirmed by Han and colleagues (2012) who 
described cannabinoid-mediated long term depression in the hippocampus in relation to the 
activation of NMDA receptors containing GluN2B subunits.  
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Two recent studies did not find any glutamate receptor alteration following postnatal Δ9-
THC exposure (Long et al., 2013; Spencer et al., 2013); however, both studies detected an aberrant 
NMDA receptor expression in Δ9-THC-treated mice carrying a genetic modification of the 
neuregulin 1 (NRG1) gene considered a schizophrenia relevant behavioral phenotype. In particular, 
adolescent Δ9-THC-treated NRG1 HET mice displayed increased NMDA receptor expression 
(Long et al., 2013) and altered expression of proteins involved in the NMDA receptor trafficking to 
the synaptic membrane (Spencer et al., 2013). Furthermore, Rubino et al. (2015) found that 
postnatal Δ9-THC exposure alters the maturational fluctuations of NMDA and AMPA units in the 
prefrontal cortex during adolescence.    
Two studies showed that Δ9-THC decreases striatal glutamate release, and that SR141716A 
is able to reverse this decrease (Orru et al., 2011; Sano et al., 2008). Interestingly, as γ-
aminobutyric acid (GABA)-ergic neurons did not appear to be particularly sensitive to Δ9-THC, it 
is noteworthy that evidence has been obtained for a selective CB1 receptor-mediated Δ9-THC 
action on glutamate-containing neurons in the nucleus accumbens (NAc; Sano et al., 2008).  
The effect of cannabis on intracerebral glutamate levels was studied for the first time more 
than 30 years ago, when it was found that no significant changes in glutamine or glutamate levels 
occurred in adult chacma baboons after they were fed with Cannabis sativa (Ames et al., 1979). 
Similarly, Hikal et al. (1988) did not report any change in glutamine or glutamic acid in rats after 
Δ9-THC exposure. However, a more recent study indicated that Δ9-THC increases extracellular 
glutamate levels; this was also associated with increased dopamine levels and decreased GABA 
levels (Pistis et al., 2002). Galanopoulos et al. (2011) described a dose-dependent Δ9-THC induced 
increases in glutamate tissue levels across several brain areas (dorsal striatum; NAc; hippocampus; 
prefrontal cortex, PFC) which presumably reflects a reduction in synaptic glutamate levels. 
Studies on glutamate enzyme activity have focused mainly on GAD activity: Edery and 
Gottesfeld  (1975) were the first to detect a GAD activity reduction in cerebellum and motor 
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cortex, but not striatum, following Δ9-THC exposure. The absence of effect in the striatum was 
confirmed by Romero and colleagues (1998). More recently, Zamberletti et al (2014) described a 
time and dose-dependent ability of Δ9-THC to reduce prefrontal GAD activity, and showed that 
hippocampal GAD activity was not affected. Only one study has assessed glutamate 
dehydrogenase (GLDH), which appeared to be peripherally increased in rabbits fed with hashish 
for a month (Ghoneim et al., 1980).  
 
3.3.4. Animal studies of effect of postnatal in vivo Δ9-THC exposure on glutamate, 
followed by additional in vitro Δ9-THC exposure 
This study design was used to evaluate the sensitivity to cannabinoids in animals 
chronically exposed to Δ9-THC. Hoffman et al (2003) reported that an electrical stimulation of 
glutamatergic afferents to the NAc is able to induce long-term depression (LTD) in vehicle-treated 
animals, and that LTD can be completely blocked by the CB1 receptor antagonist SR141716A. On 
the contrary, electrical stimulation was not able to induce LTD in brain slices from rats chronically 
treated with Δ9-THC or the CB1 receptor agonist WIN55,212-2; also, in vitro WIN55,212-2 
application was less effective in inducing LTD in chronically Δ9-THC -treated rats compared to 
controls. These data demonstrate functional tolerance, as long-term exposure to the psychoactive 
ingredient of cannabis can alter the modulatory effect of endogenous and exogenous cannabinoids 
on synaptic transmission. Another study confirmed that the ability of a cannabinoid agonist to 
inhibit glutamatergic transmission at PFC–NAc synapses is reduced after repeated exposure to Δ9-
THC (Mato et al., 2005). However, it was also found in this study that in Δ9-THC-treated mice, 
LTD can still be induced because a presynaptic mGluR2/3 (metabotropic glutamate receptor 2/3)-
dependent mechanism replaces the impaired endocannabinoid system. According to this study, 
eCB–LTD and mGluR2/3–LTD in the NAc can inhibit each other (a mGluR2/3 antagonist 
completely abolished Δ9-THC-induced LTD), despite being mediated by different receptors. Two 
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additional studies confirmed both impaired glutamatergic synaptic neurotransmission and 
functional tolerance as a consequence of prolonged cannabinoid receptor occupation by Δ9-THC 
(Hoffman et al., 2007; Tonini et al., 2006). Finally, Chen et al (2013) demonstrated that impaired 
synaptic function induced by repeated Δ9-THC exposure is associated with reduced uptake of 
glutamate by glutamate transporters in astrocytes; as a consequence, the resulting sustained 
elevation and accumulation of extracellular glutamate induces downregulation and internalization 
of glutamate receptor subunits and reduction in the density of dendritic spines in hippocampal 
neurons, leading to deficits in long-term synaptic plasticity.   
 
4. DISCUSSION 
This is the first systematic review of all studies examining the acute as well as chronic 
effect of cannabis or its main psychoactive ingredient, Δ9-THC, on the glutamate system in 
humans as well as animals. Previous reviews have mainly focused on the effects of cannabis use on 
dopamine transmission, in both animals (Kuepper et al., 2010) and humans (Ghazzaoui and Abi-
Dargham, 2014; Sami et al., 2015; van Winkel and Kuepper, 2014), indicating that although there 
is consistent evidence for time and dose-dependent effects of Δ9-THC on psychosis risk (Di Forti 
et al., 2009), the relationship between Δ9-THC and dopaminergic abnormalities is still a matter of 
contention (Sami et al., 2015). Overall, this review demonstrates that cannabis or Δ9-THC have 
definite effects on glutamate in preclinical models, affecting glutamate signalling at different 
levels. Also, taking into account the paucity of observational studies and the absence of 
experimental studies in humans, cannabis use seems to consistently affect glutamate signalling in 
the human brain. These effects are discussed in greater detail below. 
4.1. In vivo human studies 
4.1.1. Chronic cannabis use reduces glutamate-related metabolite levels in the brain  
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The largest study supported an association between chronic cannabis use and reduced levels 
of glutamate-related metabolites in basal ganglia (Chang et al., 2006). However, when focusing 
specifically on the dorsal striatum, another study suggested a gender-related vulnerability to 
cannabis-induced glutamate abnormalities (Muetzel et al., 2013). In particular, female subjects had 
lower Glx (glutamate + glutamine) metabolite levels in the context of cannabis use, while male 
individuals did not show any difference in their Glx levels with reference to their history of 
cannabis use. This neurobiological finding is not in line with the clinical evidence from a recent 
review that males admitted to hospital with a diagnosis of cannabis psychosis outnumber females 
by 4:1 (Hamilton et al., 2015). However, the available data are too limited to draw any firm 
conclusions about a possible gender-related vulnerability to cannabis-induced glutamate 
impairment.  
Two studies supported the evidence of a glutamate-related metabolite reduction in the 
anterior cingulate cortices of cannabis users (Prescot et al., 2011; Prescot et al., 2013). This finding 
was not replicated by Sung et al (2013). This study applied more rigorous criteria in order to 
control for the confounding effects of substance use and psychiatric comorbidity; however, the 
negative findings could be explained by the small sample size compared to the other studies and 
the inclusion of individuals with comorbid methamphetamine use which appeared to have no effect 
on glutamate signalling.  
Taken together, the 5 studies provide a limited amount of evidence that cannabis use affects 
the cortical and subcortical levels of glutamate-related metabolites. However, work in this area is 
limited by a heterogeneity of outcome measures (different spectral fitting methods and 
glutamatergic indices) and methods to exclude/adjust for possible confounding factors, such as 
substance use and psychiatric comorbidity. Research suggests that even low alcohol concentrations 
can inhibit the excitatory activity of NMDA receptors (Gonzales and Jaworski, 1997); also, the 
glutamatergic system is critically involved in nicotine dependence (Liechti et al., 2008) and its 
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dysfunction has been robustly associated with depression (Sanacora et al., 2012). Most 
importantly, cannabis available in the street has many different ingredients, some of which such as 
cannabidiol may oppose the effects of Δ9-THC (Bhattacharyya et al., 2010; Bhattacharyya et al., 
2012c; Bhattacharyya et al., 2015b), perhaps accounting for inconsistencies in the results from 
different studies. Perhaps acute challenge studies using different cannabinoids (Δ9-THC or 
cannabidiol) are first needed in order to further understand the effects of cannabis on glutamate in 
man. Also, no post-mortem/in vitro study has been carried out in humans; this work could add 
important information to the topic, in light of the important inter-species difference (human vs rat) 
in the effect of cannabis on dopaminergic signalling (Sami et al., 2015). Finally, all the studies 
identified used 
1
H magnetic resonance spectroscopy (
1
H-MRS), which has been reported to have 
limited spatial resolution, and present a whole tissue neurochemical measure, rather than 
distinguishing between intrasynaptic, extrasynaptic, or intracellular compartments (Poels et al., 
2014). In particular, the quantification of glutamate (Glu) and glutamine (Gln) using MRS at 
3Tesla field strength is challenging because of the overlapping multiplet structure of the coupled 
resonances (Gu et al., 2013). Even if constant-time point-resolved spectroscopy (CT-PRESS) has 
been optimized at 3 T to detect Glu, it did not resolve Gln (Gu et al., 2013). 
 
4.2. Animal studies 
4.2.1. Δ9-THC depresses glutamate synaptic transmission via CB1 receptor activation 
Evidence from animal studies indicates that Δ9-THC depresses glutamate transmission in 
cerebellar (Irie et al., 2015), striatal (Brown et al., 2003; Mato et al., 2005) and midbrain (Good 
and Lupica, 2010; Liu et al., 2010) preparations as well as hippocampal slices (Chen et al., 2013; 
Fan et al., 2010; Han et al., 2012; Hoffman et al., 2010; Hoffman et al., 2007; Shen and Thayer, 
1999; Straiker and Mackie, 2005). This has been consistently shown to be mediated by the CB1 
receptor, using different methodologies, such as potent CB1 receptor agonists (Han et al., 2012; 
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Irie et al., 2015; Liu et al., 2010; Shen and Thayer, 1999; Straiker and Mackie, 2005) and 
antagonists (Brown et al., 2003; Fan et al., 2010; Good and Lupica, 2010; Han et al., 2012; 
Hoffman et al., 2010; Irie et al., 2015; Liu et al., 2010; Shen and Thayer, 1999; Straiker and 
Mackie, 2005) or CB1 receptor genetic silencing (Fan et al., 2010; Han et al., 2012; Hoffman et al., 
2010; Liu et al., 2010; Straiker and Mackie, 2005). Also, Han and colleagues (2012) suggested that 
in vitro cannabinoid application decreases excitatory synaptic transmission via activation of 
“glutamatergic” CB1 receptors, whereas in vivo cannabinoid administration induces 
endocannabinoid mediated long-term depression (eCB-LTD) via astroglial CB1 receptor. 
 
4.2.2. Chronic Δ9-THC exposure reduces the CB1 receptor-mediated inhibition of 
glutamate synaptic transmission 
Another important finding obtained in the identified animal studies is that chronic treatment 
with Δ9-THC reduces the CB1 receptor-mediated inhibition of excitatory synaptic transmission 
(Hoffman et al., 2003; Mato et al., 2005). Impairment of eCB-LTD is attributable to prolonged 
CB1 receptor occupation and the resulting functional tolerance. Consistently, prolonged Δ9-THC 
exposure caused decreased sensitivity of glutamatergic synapses to the inhibitory effects of 
cannabinoids, even to potent CB1R agonists (Hoffman et al., 2003; Mato et al., 2005). 
Interestingly, results support an alternative presynaptic mGluR2/3–LTD at the excitatory synapses 
between the prefrontal cortex and the nucleus accumbens (PFC-NAc) in animals chronically 
exposed to Δ9-THC, which inhibit each other in occluding eCB-LTD (Mato et al., 2005).  
 
4.2.3. Δ9-THC exhibits both CB1 receptor agonist and antagonist properties, resulting in 
opposite effects on glutamate synaptic transmission 
In vitro studies clarified the relevance of the Δ9-THC partial agonist profile with reference 
to glutamatergic synaptic transmission (Shen and Thayer, 1999; Straiker and Mackie, 2005). More 
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specifically, Δ9-THC has been reported to have high potency but modest efficacy in affecting 
glutamate synaptic transmission, if compared to the potent CB1 receptor agonist WIN55,212-2 
(Shen and Thayer, 1999). Most importantly, it has been suggested that Δ9-THC can block the 
activation of CB1 receptors.  Indeed, Δ9-THC has been found to prevent (Straiker and Mackie, 
2005) and partially reverse (Shen and Thayer, 1999) WIN55,212-2-induced glutamate synaptic 
depression.     
 
4.2.4. Effects of Δ9-THC on glutamate release differ under in vivo and in vitro 
conditions and depending on the duration of the exposure 
The blockade of glutamate synaptic plasticity after prolonged Δ9-THC exposure has been 
related to an increase in glutamate release probability that occurs in Δ9-THC-tolerant mice in both 
the cerebellum (Tonini et al., 2006) and the hippocampus (Hoffman et al., 2007). A more recent 
study has proposed that impairment in hippocampal glutamate synaptic function following chronic 
Δ9-THC exposure is associated with a CB1 receptor-G beta gamma complex-protein kinase B- 
extracellular-signal-regulated kinase-mitogen activated protein kinase-nuclear factor kappa-light-
chain-enhancer of activated B cells- cyclooxygenase 2 (CB1R-Gβγ-Akt-ERK/MAPK-NF-кB-
COX-2) signalling pathway (Chen et al., 2013). Upon repeated Δ9-THC exposure, glutamate 
released from astroglial cells triggered by cyclooxygenase 2-derived prostaglandine E2 (COX2-
derived PGE2) and reduced uptake of glutamate by glutamate transporters in astrocytes would 
cause extracellular glutamate accumulation. Sustained elevation and accumulation of extracellular 
glutamate would induce down-regulation and internalization of glutamate receptor subunits and 
reduction in the density of dendritic spines, leading to deficits in long-term synaptic plasticity 
(Chen et al., 2013).  
However, the finding of a Δ9-THC-induced increase in glutamate release probability after 
prolonged in vivo exposure (Fan et al., 2010; Hoffman et al., 2007; Tonini et al., 2006) is 
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apparently in contrast with results from other in vivo studies involving administration of a single 
dose of Δ9-THC, as well as with results from  in vitro studies. In particular, in vivo exposure to a 
single dose of Δ9-THC has been associated with CB1 receptor-mediated inhibition of glutamate 
release (Orru et al., 2011; Sano et al., 2008). Similarly, it has been suggested that in vitro Δ9-THC 
application induces a decrease in presynaptic glutamate release via activation of presynaptic CB1 
receptors (Brown et al., 2003; Shen and Thayer, 1999), an effect that has been observed in cells 
treated with potent CB1 receptor agonists (Irie et al., 2015). Brown and colleagues (2003) 
proposed that striatal CB1 receptor activation decreases glutamate transporter activity and that the 
resulting increase in synaptic cleft glutamate concentration causes the activation of presynaptic 
mGluRs, which then decrease glutamate release. Consistently, this study reported that blockade of 
glutamate uptake mimics the actions of Δ9-THC in vitro: blockade of glutamate transport and 
activation of CB1 receptors act to depress glutamate transmission by a similar mechanism, and 
mGluR antagonism abolishes the depression induced by Δ9-THC (Brown et al., 2003).  
Castaldo and colleagues (2010) tried to identify the cause of the discrepancy between the 
effects of Δ9-THC on glutamate release under in vivo and in vitro conditions or prolonged and 
single dose exposure. This study indicated that in vitro application of low concentrations of Δ9-
THC was able to paradoxically promote hippocampal glutamate release in rats with no previous 
exposure. On the contrary, perinatal exposure to Δ9-THC suppressed the ability of low 
cannabinoid concentrations to promote glutamate release (Castaldo et al., 2010). The authors 
proposed that low cannabinoid concentrations enhance glutamate release in response to 
depolarization (as also shown by Tomasini et al., 2002), and that this effect is selectively lost in 
Δ9-THC-treated rats, suggesting that impaired glutamatergic neurotransmission could partially 
depend on the loss of a similar control by endocannabinoids (Castaldo et al., 2010).  
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4.2.5. Δ9-THC reduces glutamate enzyme activity affecting the normal central nervous 
system ontogeny 
A few studies addressed glutamate enzyme activity in response to Δ9-THC. The only in 
vitro study in this field reported that Δ9-THC reduces both GAD and GS activity; interestingly, 
while JWH-015, a selective CB2 receptor agonist had the same effects as Δ9-THC on GAD and 
GS activity, Arachidonyl-2'-chloroethylamide (ACEA), a selective CB1 agonist, had no effects. 
Therefore, the authors concluded that the adverse effects of Δ9-THC on glutamate enzyme activity 
are likely caused by CB2 receptor activation (Monnet-Tschudi et al., 2008). Suarez and colleagues 
(2002) confirmed a decrease in GS expression after perinatal Δ9-THC exposure. According to the 
authors, a possible explanation for this finding is that the release of glutamate is decreased, a 
hypothesis that needs further investigation. Impaired activity of the glutamate enzymes, glutamate 
cysteine ligase, modifier subunit (GCLM), glutamate dehydrogenase 1 (GLUD1) and glutamate 
oxaloacetate transaminase 1 (GOT1), has been proposed to be related to aberrant events occurring 
during the ontogeny of the central nervous system in animal embryos exposed to Δ9-THC 
(Campolongo et al., 2007). In vivo studies indicate that GAD activity is reduced in cerebellum, 
motor and prefrontal cortex, but not in the striatum and ventral midbrain (Edery and Gottesfeld; 
Garcia-Gil et al., 1999; Romero et al., 1998; Zamberletti et al., 2014). According to Zamberletti et 
al (2014), reduced GAD expression may be directly related to the altered behavior observed in 
adult Δ9-THC-treated rats. 
 
 
4.2.6. Δ9-THC alters expression, function, and maturational fluctuations of glutamate 
receptors 
It has been proposed that the impaired long-term synaptic plasticity induced by Δ9-THC is 
associated with altered expression, function, and maturational fluctuations of glutamate receptors 
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(Fan et al., 2010; Han et al., 2012; Liu et al., 2010; Rubino et al., 2015; Suarez et al., 2004b) and 
that this alteration is more pronounced in animal models of schizophrenia (Long et al., 2013; 
Spencer et al., 2013). Spencer and colleagues (2013) have suggested that increased expression of 
NMDA receptors in Δ9-THC-treated Nrg1 HET mice might increase the expression of the 
apoptotic marker PCD2 and the anandamide synthesizing enzyme NAPE-PLD, protein changes 
reflecting heightened excitotoxicity and apoptosis, and a homeostatic attempt to dampen increased 
NMDA receptor activation. Moreover, it has been proposed that Δ9-THC-induced CB1 receptor 
activation causes the insertion of higher conducting GluR2-lacking AMPA receptors into 
subcortical glutamate synapses (Good and Lupica, 2010). 
 
4.2.7. Δ9-THC decreases expression and functional activity of glutamate transporters 
Studies which have assessed the effect of prenatal exposure to Δ9-THC on expression and 
functional activity of glutamate transporters suggest a Δ9-THC-induced reduction of glial and/or 
neuronal transporters in hippocampus (GLAST; GLUT1; Castaldo et al., 2010) and cerebellum 
(GLAST; EAAC1; Suarez et al., 2004b). Collectively, these studies suggest that Δ9-THC exposure 
during brain development may alter the glutamatergic system not only during the period of drug 
exposure but also in the postnatal stage following withdrawal, supporting an association between 
abnormal maturation of the glutamatergic neuron-glia circuitry and downregulation of glutamate 
transporters. Chen and colleagues (2013) indicated that postnatal Δ9-THC exposure is able to 
affect hippocampal GLAST and GLUT1 transporters levels in a similar way. Interestingly, 
Castaldo et al (2007) reported that prenatal exposure to the cannabinoid CB1 receptor agonist 
WIN55,212-2 exhibits opposite effects to those of Δ9-THC, increasing expression and functional 
activity of GLT1 and EAAC1 glutamate transporters in rat frontal cerebral cortex, possibly due to 
one or more differences between the mode(s) of action of WIN55,212-2 (a full agonist at the CB1 
receptor) and Δ9-THC (a partial CB1R agonist). 
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4.2.8. Less conclusive evidence of an effect of Δ9-THC on brain glutamate levels 
Studies on brain neurotransmitter levels tend to support an alteration following Δ9-THC 
exposure, even if the direction of this alteration is still unclear. First studies conducted in the 
1970’s and 1980’s failed to show altered glutamate, glutamine or glutamic acid levels after in vivo 
exposure to Δ9-THC, possibly due to technical limitations (Edery and Gottesfeld, 1975; Hikal et 
al., 1998). Furthermore, while perinatal exposure has been related to reduced cortical basal 
extracellular glutamate levels (Campolongo et al., 2007; Castaldo et al., 2007), studies exploring 
effects of postnatal Δ9-THC exposure indicate an increase in cortical extracellular (Pistis et al., 
2002) and hippocampal intracellular glutamate levels (Fan et al., 2010).  Galanopoulos et al (2011) 
found cortical, striatal, as well as hippocampal increased glutamate tissue content (Galanopoulos et 
al., 2011), inferring a dose-dependent Δ9-THC-induced reduction in glutamate synaptic levels, 
possibly due to the activation of CB1 receptors at the glutamatergic presynapses in cortical and 
subcortical brain regions.  
 
4.3. Conclusion 
Together, the 41 studies discussed in this review suggest that cannabis use or exposure to its 
main psychoactive constituent, Δ9-THC, have the ability to disrupt glutamate signalling in 
preclinical models as well as humans. There is reasonably consistent evidence from animal models 
that in vitro application as well as in vivo embryonal or postnatal administration of Δ9-THC 
depresses endocannabinoid-mediated glutamate synaptic transmission, affecting glutamate release, 
enzyme activity and the expression and activity of both receptors and transporters. Also Δ9-THC 
seems to be able to agonize as well as antagonize CB1 receptors depending on the extent of 
receptor occupation, resulting in opposite effects on glutamate synaptic transmission. Finally, 
prolonged Δ9-THC exposure affects glutamate synaptic plasticity by a functional tolerance 
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mechanism, reducing the ability of CB1R agonists to inhibit glutamate synaptic transmission 
(Figure 1).  
In light of all this evidence, the finding that chronic cannabis use reduces glutamate-related 
metabolite levels in man could well be a result of excessive down-regulation of glutamate 
signalling. However, research in humans is still too limited and further investigations are needed in 
order to address this issue and its relevance for the clinical phenotype of cannabis-associated 
schizophrenia. Convergent and replicated findings from several studies suggest that dopamine 
dysregulation is the final common biological pathway for all the psychosis risk factors (Howes and 
Kapur, 2009). This hypothesis suggests that many neurochemical pathways could induce dopamine 
sensitisation. Consistently, hypofunctioning glutamate neurotransmission has been postulated to be 
the primary deficit determining the dopamine abnormalities consistently reported in schizophrenia 
(Howes et al., 2015; Snyder and Murphy, 2008). Indeed, the biological distance between Δ9-THC 
effects and glutamate abnormalities is shorter compared to that of dopamine dysregulation. 
Therefore, glutamate rather than dopamine correlates may best capture the effects of cannabis on 
the brain.  
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Figure Captions 
Figure 1. Summary of the main effects of delta-9-tetrahydrocannabinol (Δ9-THC) on glutamate 
signalling 
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↓, reduction; ↑, increase; →, no effect; +, present; Number of arrows (↓ or ↑) indicate number of 
studies; Δ9-THC, delta-9-tetrahydrocannabinol; CB1, cannabinoid receptor type 1; Gln, glutamine; 
Glu, glutamate; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; GluR1, glutamate 
receptor 1; GluR2/3, glutamate receptor 2/3; NMDA, N-methyl-d-aspartate; GluT, glutamate 
transporters; GLAST, L-glutamate/L-aspartate transporter; EAAC1, excitatory amino acid carrier 1; 
GLT1, glutamate transporter 1; GAD, glutamic acid decarboxylase; GS, glutamine synthetase; 
GLDH, glutamate dehydrogenase; GABA, gamma-aminobutyric acid 
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Tables 
Table 1. Studies included in review 
  
    
Study Type of study Region of Interest Site of abnormality in Glutamate Pathway 
Chang et al., 2006 MR Imaging studies in chronic human users Basal ganglia, Frontal white matter Glutamate-related metabolites 
Prescot et al., 2011 MR Imaging studies in chronic human users Anterior cingulate cortex Glutamate-related metabolites 
Muetzel  et al., 2013 MR Imaging studies in chronic human users Dorsal striatum Glutamate-related metabolites 
Prescot et al., 2013 MR Imaging studies in chronic human users Anterior cingulate cortex Glutamate-related metabolites 
Sung et al., 2013 MR Imaging studies in chronic human users Anterior cingulate cortex Glutamate-related metabolites 
Shen and Tayer, 1999 In vitro experiment in embryonally exposed animal cells Hippocampus Glutamate synaptic transmission 
Monnet-Tschudi et al., 2008 In vitro experiment in embryonally exposed animal cells Mixed brain cell aggregates Glutamate enzyme activity 
Tomasini et al., 2002 In vitro experiment in postnatally exposed animal cells Cerebral Cortex Extracellular glutamate levels, glutamate uptake, uptake  
Brown et al., 2003 In vitro experiment in postnatally exposed animal cells Striatum Glutamate release, uptake, synaptic transmission 
Straiker and Mackie, 2005 In vitro experiment in postnatally exposed animal cells Hippocampus Glutamate synaptic transmission 
Hoffman et al., 2010 In vitro experiment in postnatally exposed animal cells Hippocampus Glutamate synaptic transmission 
Irie et al., 2015 In vitro experiment in postnatally exposed animal cells Cerebellum Glutamate synaptic transmission 
Castaldo et al., 2007 In vivo embryonal exposure in animals Right frontal cortex Extracellular glutamate levels, glutamate uptake, transporters  
Garcia-Gil et al., 1999 In vivo embryonal and postnatal exposure in animals Basal ganglia Glutamate enzyme activity 
Suarez et al., 2002 In vivo embryonal and postnatal exposure in animals Cerebellum (cortex) Glutamate enzyme activity 
Suarez et al., 2004 (a) In vivo embryonal and postnatal exposure in animals Cerebellum Glutamate transporters 
Suarez et al., 2004 (b) In vivo embryonal and postnatal exposure in animals Cerebellum Glutamate receptors 
Campolongo et al., 2007 In vivo embryonal and postnatal exposure in animals Prefrontal cortex Glutamate receptors, enzyme activity, synaptic transmission 
Castaldo et al., 2010 In vivo embryonal and postnatal exposure in animals Hippocampus Glutamate release, uptake, transporters 
Edery and Gottesfeld, 1975 In vivo postnatal exposure in animals Cerebellum, striatum, motor cortex Glutamate enzyme activity 
Ames et al., 1979 In vivo postnatal exposure in animals Right temporal lobe Glutamate, glutamine 
Ghoneim et al., 1980 In vivo postnatal exposure in animals Peripheral Glutamate enzyme activity 
Hikal et al., 1988 In vivo postnatal exposure in animals Hippocampus Glutamic acid, glutamine 
Romero et al., 1998 In vivo postnatal exposure in animals Striatum, ventral midbrain Glutamate enzyme activity 
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Pistis et al., 2002 In vivo postnatal exposure in animals Prefrontal cortex Extracellular glutamate levels 
Sano et al., 2008 In vivo postnatal exposure in animals Nucleus accumbens Glutamate release 
Fan et al., 2010 In vivo postnatal exposure in animals Hippocampus Glutamate receptors, synaptic transmission 
Good and Lupica, 2010 In vivo postnatal exposure in animals PPN, ventral tegmental area Glutamate synaptic transmission 
Liu et al., 2010 In vivo postnatal exposure in animals Ventral tegmental area Glutamate synaptic transmission 
Galanopoulos et al., 2011 In vivo postnatal exposure in animals PFC, DS, NAc, HPC, AMYG, HTH Glutamate tissue levels 
Orrú et al., 2011 In vivo postnatal exposure in animals Striatum Glutamate release 
Han et al., 2012 In vivo postnatal exposure in animals Hippocampus Glutamate synaptic transmission 
Long et al., 2013 In vivo postnatal exposure in animals HPC, Cg, Aco, PMCo Glutamate receptors 
Spencer et al., 2013 In vivo postnatal exposure in animals Hippocampus Glutamate receptors 
Zamberletti et al., 2014 In vivo postnatal exposure in animals Prefrontal cortex, hippocampus Glutamate enzyme activity 
Rubino et al., 2015 In vivo postnatal exposure in animals Prefrontal cortex Glutamate receptors 
Chen et al., 2013 In vivo postnatal exposure in animals + in vitro experiment Hippocampus Glutamate receptors, synaptic transmission 
Hoffman et al., 2007 In vivo postnatal exposure in animals + in vitro experiment Hippocampus Glutamate receptors, synaptic transmission 
Tonini et al., 2006 In vivo postnatal exposure in animals + in vitro experiment Cerebellum Glutamate synaptic transmission 
Mato et al., 2005 In vivo postnatal exposure in animals + in vitro experiment Nucleus accumbens Glutamate synaptic transmission 
Hoffman et al., 2003 In vivo postnatal exposure in animals + in vitro experiment Nucleus accumbens Glutamate release, synaptic transmission 
    MR, Magnetic Resonance; PPN, pedunculopontine nucleus; PFC, prefrontal cortex; DS, dorsal striatum; NAc, nucleus accumbens; HPC, hippocampus; AMYG, amygdala; HTH, hypothalamus;  
Cg. Cingulate cortex; Aco, Auditory cortex; PMCo, posteromedial cortical amygdaloid nucleus 
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Table 2A. Summary of human neuroimaging studies of effect of chronic cannabis use on glutamate-related metabolites     
         
Study Aim of study Population n Cannabis use Controls Region of interest Results Imaging analysis 
Chang et al 
(2006) 
Glu metabolite concentration in 
chronic CBS and HIV 
1. 24 CBS users                             
2a. 24 only CBS  
2b. 21 HIV+CBS  
2c. 21 HIV subjects  
96 CBS interview 30 healthy 
controls  
Basal ganglia                                                                              
______________________                                                     
Frontal white matter 
1. ↓(-9.5%, p=0.05)                      
2a. ↓(-12%, p = 0.03)     
2b. ↓(-13%, p = 0.03)               
2c. NS                                 
________________________                         
1. NS                                                           
2a.↓ 
2b. NS 
2c.↓       
1H magnetic 
resonance 
spectroscopy 4T 
MRI system 
Prescot et al 
(2011) 
Glu metabolite concentration in 
chronic CBS  
17 CBS users 34 urine analysis +  CBS interview 17 healthy 
controls 
Anterior cingulate cortex ↓ (-15%, p<0.01) 1H magnetic 
resonance 
spectroscopy 3T 
MRI system 
Muetzel et al 
(2013) 
Glu metabolite concentration in 
chronic CBS 
27 CBS users 53 Personal Experience Inventory (PEI) 26 healthy 
controls 
Dorsal striatum NS overall group; group by sex 
interaction, p=0.01:   ↓ in F (-
12.5%, p=0.04), NS in M   
1H magnetic 
resonance 
spectroscopy 3T 
MRI system 
Prescot et al 
(2013) 
Glu metabolite concentration in 
chronic CBS 
13 CBS users 29 urine analysis +  CBS interview 16 healthy 
controls 
Anterior cingulate cortex ↓ (-14%, p=0.01) 1H magnetic 
resonance 
spectroscopy 3T 
MRI system 
Sung et al 
(2013) 
Glu metabolite concentration in 
chronic CBS and MA 
1. 8 CBS+MA users                                
2. 9 MA users 
27 K-SADS diagnostic interview 10 healthy 
controls 
Anterior cingulate cortex 1. NS                                                     
2. NS 
1H magnetic 
resonance 
spectroscopy 3T 
MRI system 
 
Glu, glutamate; CBS, cannabis; HIV, Human Immunodeficiency Virus; MA, methamphetamine; K-SADS, Kiddie-Schedule for Affective Disorders and Schizophrenia; M, male; F, female; MRI, magnetic resonance system 
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Table 2B. Methodological quality of imaging studies of effect of chronic cannabis use on glutamate-related metabolites 
Study Defined study 
population 
Adequate 
exposure 
Control Comparability of 
Subjects 
Statistical 
analysis 
Outcome 
measurement 
Mental health 
comorbidity 
Excluded/adjusted 
for tobacco use 
Excluded/adjusted 
for alcohol use 
Excluded/ 
adjusted for 
substance use 
Funding or 
sponsorship 
 
Chang et al  
(2006) 
✓ History of 
chronic CBS 
use - last CBS 
use between 0 
and 240 months 
before scanning 
✓ use of 
CBS>4days/week 
for at least 12 
months 
✓ ✓ Demographic 
characteristics matched 
(sex, age, 
neuropsychological 
tests) 
✓ 
ANOVA, 
ANCOVA 
✓ Glu metabolite 
levels corrected 
for the partial 
volume of 
cerebrospinal fluid 
✓ Exclusion 
criterion 
✓ Trend for 
difference in daily 
tobacco use 
(CBS>HC), but this 
was corrected in 
analyses 
✓ Exclusion 
criterion 
✓ Exclusion 
criterion 
✓ Declared  
Prescot et al 
(2011) 
✓ Current 
chronic CBS 
users 
✓ use of CBS at 
least 100 times in 
the last 12 months 
✓ ✓ Significant 
differences in sex and 
age, but these were 
corrected 
✓ 
ANOVA, 
ANCOVA 
✓ Glu metabolite 
levels/water 
✓/✕ 2 CBS users 
with treated 
depression, not 
corrected 
✕ ✕ 3 CBS users with 
history of alcohol 
abuse and/or 
dependence, not 
corrected 
✓ Exclusion 
criterion 
✓ Declared  
Muetzel et al 
(2013) 
✓ Current 
chronic CBS 
users; briefly 
abstinent (at 
least 12h before 
scanning) 
✓ use of 
CBS>4days/week 
for at least 12 
months, age at 
first use<17years, 
DSM-IV criteria 
for CBS abuse or 
dependence 
✓ ✓ Demographic 
characteristics matched 
(sex, age, IQ), 
however age corrected 
and sex differences 
examined 
✓ 
ANCOVA 
✓ Glx (Glu+Gln) 
metabolite 
levels/tCr 
✓ Most participants 
were free of a DSM-
IV Axis I diagnosis 
and none had 
psychosis 
✓/✕Exclusion 
criterion only in 
CBS users 
✓ Significant 
difference in alcohol 
use (CBS>HC), but 
this was corrected 
✓ Exclusion 
criterion 
✓ Declared  
Prescot  et al 
(2013) 
✓ Current 
chronic CBS 
users; 7 (54%) 
having used 
CBS within the 
24h before 
scanning 
✓ use of CBS at 
least 100 times in 
the last 12 months 
✓ ✓ Significant 
differences in sex and 
age, but these were 
corrected 
✓ 
ANOVA, 
ANCOVA 
✓ Glu metabolite 
levels/water 
✓Significant 
difference in HAM-
D (CBS > HC) and 2 
CBS users with 
treated depression, 
but these were 
corrected/excluded 
✓ 3 CBS users with 
history of 
past/current nicotine 
use, but this was 
corrected/excluded 
✓ 3 CBS users with 
history of alcohol 
abuse and/or 
dependence, but this 
was 
corrected/excluded 
✓ Exclusion 
criterion 
✓ Declared  
Sung et al 
(2013) 
✓ Current 
chronic CBS 
users 
✓ diagnostic 
criteria for current 
MA/MA+CBS 
dependence 
✓ ✓ Demographic 
characteristics matched 
(sex, language, 
income, repeated 
grades); trend for 
differences in age and 
education, but these 
were corrected 
✓ 
ANOVA, 
ANCOVA 
✓ Glx (Glu+Gln) 
metabolite 
levels/PCr+Cr 
✓ No individual 
met diagnostic 
criteria for a DSM-
IV Axis I disorder 
✓ No significant 
difference in tobacco 
use (lifetime n 
cigarettes, duration 
in months), however 
corrected  
✓ Exclusion 
criterion, no 
significant 
difference, however 
corrected  
✓ Exclusion 
criterion 
✓ Declared  
CBS, cannabis; HC, healthy controls; h, hours; DSM-IV, The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition; MA, methamphetamine; IQ, intelligence quotient; ANOVA, analysis of variance; ANCOVA, analysis of 
covariance; Glu, glutamate; Gln, glutamine; tCr, total creatine; PCr, phosphocreatine; HC, healthy controls; ✕, no information provided 
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Table 3. Summary of animal studies of effect of in vitro Δ9-THC exposure on glutamate    
                 
Study Animal 
model 
Stage of 
development 
Sex Weight Genetics Δ9-THC 
application 
dosage 
Other used 
cannabinoi
ds (dosage) 
Controls Region of 
interest 
Synaptic 
transmission 
Enzyme 
activity 
Neurotr. 
release 
Neurotr. 
uptake 
Extracellular 
levels 
Method Statistics 
Shen and 
Thayer 
(1999) 
✓                     
rat 
✓                      
ED 17, then 
cultures 
grown for at 
least 12 days 
✕ ✕ NA ✓                                   
1. 100 nM or 
1 μM 
✓                                                   
2. 
WIN55,212-
2 (100 nM)           
3. 
SR141716A 
(300 nM) 
✕ ✓              
Hippocampus 
✓                                                                                  
1. 40%↓Ca2+ 
spiking, 
independently of 
dosage, 
prevented by SR; 
57%↓EPSCa                                      
2. 100%↓Ca2+ 
spiking, partially 
reversed by 
THC; 
96%↓EPSCa                                        
3. NS                                                                                 
1+2(combined). 
75%↓EPSCa 
NA NA NA NA ✓                                   
Electrophysiology 
✓ 
ANOVA 
Monnet-
Tschudi 
et al 
(2008) 
✓                     
rat 
✓                        
ED 16, then 
cultures 
grown for 24 
days 
✕ ✕ NA ✓                                   
1. 2 and 5 
μM at day 
24, then 1 
and 2 μM at 
day 25 and 
every 2nd 
day for 10 
days (up to 
day 35) 
✓                                                
2. JWH-015 
(as for Δ9-
THC)                                    
3. ACEA (as 
for Δ9-THC) 
✓ ✓                               
Mixed brain 
cell aggregates 
NA ✓                                       
1.ST and 
RT↓GAD;            
only RT↓GS                    
2.ST and 
RT↓GAD;            
only RT↓GS              
3. NS 
NA NA NA ✓                   
Radiometric assay 
✓ 
ANOVA 
Tomasini 
et al 
(2002) 
✓                     
rat 
(Sprague 
Dawley) 
✓                          
PND 1 
✕ ✕ NA ✓                                      
1. 0.01, 0.3, 
3, 300, and 
1000 nM 
✓                                          
2. 
SR141716A 
(10 nM)  
✓ ✓                           
Cerebral Cortex 
NA NA ✓                    
1.↑KCl-
evoked at 
minimum 
dosage 
✓                                      
1. NS 
✓                               
1.↑ 
concentration 
dependent, 
prevented by 
SR 
✓                                                                        
fluorimetric 
HPLC, LSC 
✓ 
ANOVA 
Brown et 
al (2003) 
✓                      
rat 
(Sprague 
Dawley) 
✕ ✓ 
male 
✓             
250-300 
gm 
NA ✓                                  
1. 10 μM 
✓                                          
2. 
SR141716A 
(100 nM)                          
3. AM251 
(500 nM) 
✓ ✓                            
Striatum 
✓                                                         
1. ↓spiking, 
prevented by SR 
and AM, 
partially 
reversed by AM 
after THC 
washout 
✕ ✓                              
1.↓K2+- 
evoked dose 
dependent, 
prevented 
by SR; NS 
basal                  
2. NS 
✓                              
1.↓, dose 
dependent, 
prevented 
by SR                        
2. NS 
NA ✓                   
Radiometric 
assay, 
Electrophysiology 
✓ 
ANOVA 
47 
 
Straiker 
and 
Mackie 
(2005) 
✓                 
mouse 
✓                   
PND 0-2 
✕ ✕ ✓                  
CB1R 
WT (+/+) 
and KO 
(-/-) 
✓                                      
1. increasing 
up to 10 μM, 
then 
exceeding 
this dosage 
✓                                             
2. 
WIN55,212-
2 (100 nM)                              
3. 2-AG (1-
10 μM)                          
4. 2-AGE 
(10 μM)                     
5. AEA (4.5 
μM)                           
6. HU-210 
(100 nM)                        
7. 
SR141716A 
(100 nM) 
✕ ✓                        
Hippocampus 
(neurones 
isolated from 
the CA1-CA3 
region) 
✓                                                       
1. NS                                                                     
2. ↓EPSC, absent 
in CB1R KO, 
prevented by 
THC                                       
3. ↓EPSC, absent 
in CB1R KO, 
recovered on 
washout                                        
4. ↓EPSC, absent 
in CB1R KO, not 
recovered on 
washout                                        
5. ↓EPSC, absent 
in CB1R KO, not 
recovered on 
washout, 
reversed by SR                                     
6. ↓EPSC, absent 
in CB1R KO, 
prevented only 
by THC 
overnight (∼18 h) 
NA NA NA NA ✓                                   
Electrophysiology 
✓                  
t-test 
Hoffman 
et al 
(2010) 
✓                
a. rat                
b. mouse 
(C57BL/6
J) 
✓                        
a. PNW 4-6      
b. PNW 4-12 
✓ 
male 
✕ ✓                  
b. CB1R 
WT (+/+) 
and KO              
(-/-) 
✓                                     
1. 10 μM 
✓                                          
2. 
WIN55,212-
2 (500 nM)                            
3. AM251 (1 
μM) 
✕ ✓              
Hippocampus 
✓                                                      
1. ↓fEPSP in rats, 
prevented by 
AM, NS in mice, 
absent in CB1R 
KO                                              
2. ↓fEPSP in rats, 
NS in mice 
NA NA NA NA ✓                                   
Electrophysiology 
✓ 
ANOVA 
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Δ9-THC, delta-9-tetrahydrocannabinol; ICR, imprinting control region; ED, embryonal day; PND, postnatal day; PNW, postnatal week; ✕, no information provided; CB1R, cannabinoid receptor 1; WT, wildtype; KO, knockout; SR141716A, rimonabant; ACEA, arachidonyl-2'-
chloroethylamide; 2-AG, 2-arachidonoylglycerol; 2-AGE, 2-arachidonyl glyceryl ether or noladin; AEA, anandamide; MAM-2201, 4'-methyl-AM-2201, 5"-fluoro-JWH-122; JWH-018, 1-pentyl-3-(1-naphthoyl)indole) or AM-678; AtT-20 cells, murine tumor line; NS, not significant; NA, 
not applicable; EPSCa, excitatory postsynaptic current amplitude; fEPSP, field excitatory postsynaptic potentials; PF-PC, parallel fiber-Purkinje cell ; PPR, paired-pulse ratio; CV, coefficient of variation; q-EPSC, quantal EPSC; CF-PC, climbing fiber-Purkinje cell; Neuotr., 
neurotransmitter; ST, single treatment; RT, repeated treatment; GAD, glutamic acid decarboxylase; GS, glutamine synthetase; HPLC, high-performance liquid chromatography; LSC, liquid scintillation counting; ANOVA, analysis of variance 
Irie 
(2015) 
✓                
mouse 
(ICR) 
✓                           
PND 20-
57/PND 14-
20 
✓ 
either 
✕ NA ✓                                 
1. increasing 
0.1-100 μM 
✓                                                         
2. MAM-
2201 (0.1-
100 μM)                   
3. 
WIN55,212-
2 (0.1-100 
μM)                                                         
4. JWH-018 
(0.1-100 
μM)                     
5. AM251 (5 
μM) 
✓ ✓                       
Cerebellum                
(AtT-20 cells) 
✓                                                       
1.↓PF-PC 
EPSCa, not 
concentration 
dependent; 
↑PPR; ↑CV;                                                            
2. ↓PF-PC 
EPSCa, 
concentration 
dependent, 
prevented by 
AM; ↑PPR; ↑CV; 
↓ PF-PC qEPSCf 
(NS qEPSCa); 
↓CF-PC EPSC                                                                 
3. ↓PF-PC 
EPSCa, ↑PPR, 
↑CV                                               
4. ↓PF-PC 
EPSCa, 
concentration 
dependent  
NA NA NA NA ✓                                   
Electrophysiology 
✓                  
t-test 
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Table 4. Summary of animal studies of effect of embryonal in vivo Δ9-THC exposure on glutamate          
                 
Study Animal 
model 
Stage of 
development 
(when 
studied) 
Sex Weight Δ9-THC 
way of 
admin., 
period, 
dosage  
Other used 
cannabinoids 
(way         of 
admin., period, 
dosage) 
Controls Region of 
interest 
Enzyme 
activity 
Neurotr. 
release 
Neurotr. 
uptake 
Extracellula
r levels 
Neurotr. 
transporters 
Neurotr. 
receptors 
Method Statistics 
Castaldo et 
al (2007) 
✓                     
rat 
✓                          
PND 40 
✓ 
male 
✕ ✓                                   
1. PO in 
dams, 
daily, from 
GD 5 to 
GD 20, 5 
mg/kg 
✓                                                         
2. WIN55,212-
2                         
(SC, daily, from 
GD 5 to GD 20, 
0.5 mg/kg)             
✓ ✓                                        
Right frontal 
cortex 
NA NA ✓                              
2.↑Vmax in 
synaptosomes, 
time 
dependent (NS 
Km) 
✓                                            
1. ↓ basal                                  
2. ↓ basal 
✓                                                                          
2. ↑GLT1;
↑EAAC1;  NS 
GLAST (NS 
GLT1, EAAC1, 
and GLAST 
transcripts) 
NA ✓                                                        
in vivo MD, 
fluorimetric 
HPLC, LSC, 
WB analysis, 
ICC, RT-PCR 
analysis 
✓                                 
t-test, 
ANOVA, 
regression 
analysis 
Garcia-Gil 
et al (1999) 
✓                     
rat 
✓                          
> PNW 10 
✓ 
either 
✓ 
recorded 
in dams 
from GD 0 
to GD 20 
(200-250 
gm), and 
in litter 
✓                                   
PO in 
dams, 
daily, from 
GD 5 to 
PND 24, 5 
mg/kg 
NA ✓ ✓substantia 
nigra/ ventral 
tegmental area, 
globus pallidus, 
caudate-
putamen/ 
nucleus 
accumbens 
✓                                     
NS GAD 
NA NA NA NA NA ✓                                                     
Radiometric 
assay 
✓                     
ANOVA 
Suárez et al            
(2002) 
✓                     
rat 
✓                          
PND 20, 
PND 30, 
PND 70    
✓ 
either 
✕ ✓                                   
PO in 
dams, 
daily, from 
GD 5 to 
PND 20, 5 
mg/kg 
NA ✓ ✓                                    
Cerebellum 
(cortex) 
✓                                                         
↓ GS, not 
reversed at 
PND 70 in 
M, 
completely 
reversed at 
PND 70 in F                                      
NA NA NA NA NA ✓                                                 
IHC for 
microscopy and 
morphometry, 
WB analysis 
✓                     
ANOVA 
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Suárez et al 
(2004a) 
✓                     
rat 
✓                          
PND 20, 
PND 30, 
PND 70    
✓ 
either 
✕ ✓                                   
PO in 
dams, 
daily, from 
GD 5 to 
PND 20, 5 
mg/kg 
NA ✓ ✓                                    
Cerebellum  
NA NA NA NA ✓                                                                             
↓GLAST, not 
reversed at 
PND70, M<F 
at PND20 
(WB) and 70 
(IHC); 
↓EAAC1, not 
reversed in 
IHC at PND70, 
but reversed in 
WB at PND70 
for M, and 
PND30 and 70 
for F 
NA ✓                                  
IHC for 
microscopy and 
morphometry, 
WB analysis 
✓                                 
t-test 
Suárez et al  
(2004b) 
✓                     
rat 
✓                          
PND 20, 
PND 30, 
PND 70    
✓ 
either 
✕ ✓                                   
PO in 
dams, 
daily, from 
GD 5 to 
PND 20, 5 
mg/kg 
NA ✓ ✓                                    
Cerebellum 
NA NA NA NA NA ✓                                                                             
continuous ↓ 
GluR1, not 
reversed at 
PND70 (↑ 
from PND20 
to 30 in 
CON); 
continuous ↓ 
GluR2/3, not 
reversed at 
PND70 (↑ 
from PND20 
to 70 in 
CON)  
✓                                               
IHC for 
microscopy and 
morphometry, 
WB analysis 
✓      
ANOVA 
Campolongo 
et al (2007) 
✓                     
rat 
✓                          
PND 80 
✓ 
male 
✓ 
recorded 
in dams 
from GD 
15 to PND 
9, and in 
litter 
✓                                   
PO in 
dams, 
daily, from 
GD 15 to 
PND 9, 5 
mg/kg 
NA ✓ ✓                                        
Prefrontal 
cortex 
✓                                                                             
↓GCLM;                
↓ GLUD1;  
↑GOT1  
NA NA ✓                                            
↓ basal                                   
NA ✓                                                                             
↓GRIP2;                       
↓ GRID2;  
↓GRIK1;  
↑GRIK3  
✓                                                                      
microarray 
analysis, in vivo 
MD, 
fluorimetric 
HPLC 
✓                  
t-test, 
ANOVA 
Castaldo et 
al (2010) 
✓                     
rat 
✓                          
PND 40 
✓ 
male 
✓ 
recorded 
in dams 
(250-280 
gm), and 
in litter 
✓                                   
1. PO in 
dams, 
daily, from 
GD 15 to 
PND 9, 5 
mg/kg               
2. in vitro 
application 
of 0.1 μM 
at PND 40 
✓                                                         
3. SR141716A                     
(in vitro 
application of 
100 nM at PND 
40) 
✓ ✓                                        
Hippocampus 
NA ✓                                            
1. ↓basal,           
↓K+-evoked         
2. ↓ in THC 
rats                                    
3. reversed 
K+-evoked ↑ 
in CON                   
✓                                            
1. ↓ 
NA ✓                                                                              
1. ↓GLT1; 
↓GLAST;  NS 
EAAC1   
NA ✓                                                        
fluorimetric 
HPLC, LSC, 
WB analysis 
✓                                 
t-test, 
ANOVA 
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Δ9-THC, delta-9-tetrahydrocannabinol; PND, postnatal day; PNW, postnatal week; ✕, no information provided; admin., administration; SR141716A, rimonabant; GD, gestational day; PO, per os; SC, subcutaneously; NA, not applicable; GAD, glutamic acid 
decarboxylase; GS, glutamine synthetase; neurotr., neurotransmitter; M, male; F, female; GCLM, glutamate cysteine ligase, modifier subunit; GLUD1, glutamate dehydrogenase 1; GOT1, glutamate oxaloacetate transaminase 1; GLT1, glutamate transporter 1; EACC1, 
excitatory amino acid carrier 1; GLAST, L-glutamate/L-aspartate transporter; GluR1, glutamate receptor 1; CON, controls; GluR2/3, glutamate receptor 2/3; GRIP2, glutamate receptor-interacting protein 2; GRID2, glutamate receptor, ionotropic, delta 2; GRIK1, 
glutamate receptor, ionotropic, kainate 1; GRIK3, glutamate receptor, ionotropic, kainate 3; MD, microdialysis; HPLC, high-performance liquid chromatography; LSC, liquid scintillation counting; WB, western blot;  ICC, immunocytochemistry, RT-PCR, real-time 
polymerase chain reaction; IHC, immunohistochemistry; ANOVA, analysis of variance  
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Table 5. Summary of animal studies of effect of postnatal in vivo Δ9-THC exposure on glutamate     
                 
Study Animal 
model 
Stage of 
development  
Sex Weight Genetics Δ9-THC 
way of 
admin., 
period, 
dosage  
Other used 
cannabinoids 
(way of 
admin., period, 
dosage) 
Controls Region of 
interest 
Synaptic 
transmission 
Enzyme 
activity 
Neurotr. 
release 
Intracerebral 
levels 
Neurotr. 
receptors 
Method Statistics 
Edery and 
Gottesfeld 
(1975) 
✓                     
rat 
(albino) 
✕ ✓ 
either 
✓                         
170-200 
gm 
NA ✓                                                     
IP, daily 
(repeated/s
ingle), for 
14 
consecutiv
e days, 20 
mg/kg 
NA ✓ ✓                                
Cerebellum, 
striatum, motor 
cortex 
NA ✓                                                         
↓ GAD in 
cerebellum 
and motor 
cortex, NS in 
striatum  
NA NA NA ✓                                                     
Radiometric assay 
✓                                 
t-test 
Ames et al              
(1979) 
✓                     
adult 
chacma 
baboon 
✕ ✓ 
either 
✕ NA ✓                                                        
PO, daily, 
for 15 
consecutiv
e days, or 
25 days 
with a 3-
day 
interval, 
10% 
cannabis 
sativa 
NA ✓ ✓                                           
Right temporal 
lobe                               
NA NA NA ✓                                          
NS Glutamine                    
NS Glutamate 
NA ✓                                 
Brain biopsy 
✕ 
Ghoneim et al 
(1980) 
✓                     
rabbit 
✕ ✕ ✕ NA ✓                                                         
PO, every 
other day, 
over 1 
month, 
hashish                      
NA ✕ ✓                                                 
Peripheral 
NA ✓                                                         
↑ GLDH 
compared to 
baseline levels  
NA NA NA ✕ ✕ 
Hikal et al              
(1988) 
✓                     
rat  
✕ ✓  male ✕ NA ✓                                                        
IP, single 
administrat
ion, 20 or 
50 mg/kg 
NA ✓ ✓                                        
Hippocampus 
NA NA NA ✓                                       
NS Glutamine                
NS Glutamic 
acid 
NA ✓                                                                        
HPLC 
✕ 
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Romero et al 
(1998) 
✓                     
rat  
✓                          
> PNW 8 
✓  male ✕ NA ✓                                                         
1. IP, 
single 
administrat
ion, 5 
mg/kg             
✓                             
2. HU210 (IP, 
single 
administration, 
50 μg/mg)          
3. SR141716A 
(IP, single 
administration, 
3mg/kg)                         
✓ ✓                                   
Striatum, 
ventral 
midbrain 
NA ✓                                                
1. NS GAD, 
either after SR 
or vehicle                                         
2. NS GAD, 
either after SR 
or vehicle 
NA NA NA ✓                                                     
Radiometric assay 
✓                                 
t-test, 
ANOVA 
Pistis et al              
(2002) 
✓                     
rat 
(albino) 
✕ ✓  male ✓                       
250-280 
gm 
NA ✓                                                         
1. IV, 
single 
administrat
ion, 1 
mg/kg             
✓                             
2. SR141716A 
(IV, single 
administration, 
1 mg/kg)             
✕ ✓                                        
Prefrontal 
cortex 
NA NA NA ✓                                                        
1.↑ basal EGL, 
prevented by 
SR                                  
2. NS 
NA ✓                                                                        
in vivo MD 
✓                     
ANOVA 
Sano et al               
(2008) 
✓                     
rat 
(Wistar) 
✓                          
PNW 7 
✓  male ✓                       
200-250 
gm 
NA ✓                                                         
1. IP, 
single 
administrat
ion, 10 
mg/kg             
✓                             
2. SR141716A 
(IP, single 
administration, 
10 mg/kg)             
✓ ✓                                     
Nucleus 
accumbens 
NA NA ✓                                                         
1. ↓, 
reversed 
by SR 
NA NA ✓                                                                        
in vivo MD 
✓                     
ANOVA 
Fan et al                
(2010) 
✓                
mouse 
(C57BL
/6J) 
✓                          
PNW 6-9 
✓ 
either 
✕ ✓                  
CB1R WT 
(+/+) and 
KO (-/-) 
✓                                                     
1. IP, 
daily, for 7 
consecutiv
e days, 10 
mg/kg 
✓                                 
2. SR141716A 
(IP, for 7 
consecutive 
days, 5 mg/kg)             
✓ ✓                                        
Hippocampus 
✓                                                         
1. ↓fEPSP 
(↓of LTP), 
prevented 
by SR, 
absent in 
CB1R KO; 
↓PPR; 
↑EPSCf 
NA ✓                                                         
1. ↑ basal 
✓                            
1.↑ IGL 
✓                                      
1. ↓GluR1, 
GluN2A, and 
GluN2B total, 
surface , and 
mRNA, 
prevented by 
SR, absent in 
CB1R KO (NS 
GluN1 and 
GluR2) 
✓                                                                        
WB analysis, RT-
PCR analysis 
✓                                 
t-test, 
ANOVA 
Good and 
Lupica (2010) 
✓                     
rat  
✓                          
PND 14-19 
✕ ✕ NA ✓                                                         
1. IP, 
single 
administrat
ion, 10 
mg/kg             
✓                             
2. AM251 (IP, 
single 
administration, 
2 mg/kg             
✓ ✓                                         
PPN, ventral 
tegmental area 
✓                                                         
1. ↓EPSC 
(LTD), ↑RI 
of evoked 
EPSC, and 
↓post LTD 
RI in PPN, 
prevented 
by AM; NS 
intra-VTA 
stimulation 
NA NA NA NA ✓                                   
Electrophysiology 
✓                     
ANOVA 
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Liu et al             
(2010) 
✓                     
rat  
✓                          
PND 16-92 
✓  male ✕ ✓                  
CB1R WT 
(+/+) and 
KO (-/-, 
using 
CB1R 
shRNA) 
✓                                                         
1. IP, daily 
(single), 
for 5 
consecutiv
e days, 5 
mg/kg             
✓                             
2. HU210 (IP, 
daily, single, for 
5 consecutive 
days, 100 
μg/kg)                         
3.AM281 (IP, 
daily, single, for 
5 consecutive 
days, 3 mg/kg)  
✓ ✓                                          
ventral 
tegmental area 
✓                                                         
1. ↓fEPSP 
(LTD)                             
2. ↓fEPSP 
(LTD), 
prevented 
by AM and 
absent in 
CB1R 
shRNA  
NA NA NA ✓                                      
2. LTD via 
activation of 
GluN2B and 
postsynaptic 
endocytosis of 
GluR1/GluR2 
✓                                   
Electrophysiology
, WB analysis 
✓                                 
t-test, 
ANOVA 
Galanopoulos 
et al (2011) 
✓                     
rat  
✓                          
PND 80-90 
✓  male ✓                       
250-300 
gm 
NA ✓                                                         
1. IP, 
single 
administrat
ion, 0.75 
or 3 mg/kg             
✓                             
2. WIN55,212-
2 (IP, single 
administration, 
0.1 or 1 mg/kg)             
✓ ✓                            
Prefrontal 
cortex, DS, 
NAc, 
Hippocampus, 
AMYG, HTH 
NA NA NA 1.↑tissue levels 
in PFC, DS, 
NAc, HPC; NS 
AMYG and 
HTH 2. ↑ tissue 
levels in PFC, 
NAc, and 
HPC; ↓ in 
AMYG and 
HTH; NS in 
DS 
NA ✓                         
HPLC 
✓                     
ANOVA 
Orrú et al                
(2011) 
✓                     
rat  
✕ ✓  male ✓                       
300-350 
gm 
NA ✓                                                         
1. IP, 
single 
administrat
ion, 3 
mg/kg             
✓                             
2. SR141716A 
(IP, single 
administration, 
1 mg/kg)             
✓ ✓                                   
Striatum 
NA NA ✓                                                         
1. ↓, 
reversed 
by SR                              
2. NS 
NA NA ✓                                                                        
in vivo MD 
✓                     
ANOVA 
Han et al                
(2012) 
✓                
mouse 
(C57BL
/6JOlaH
sd)  
✓                          
a. PNW 6-8       
b. PNW 10-
16 
✓  male ✕ ✓                  
CB1R WT 
(+/+) and 
KO (-/-, 
also using 
CB1R 
shRNA) 
✓                                                         
1. IP, 
single 
administrat
ion, 5 
mg/kg             
✓                             
2. HU210 (IP, 
single 
administration, 
0.1 or 0.5 
mg/kg; intra-
CA1 infusion)                                                   
3. AM281 (IP, 
single 
administration, 
dosage of 3 
mg/kg)             
✓ ✓                                        
Hippocampus 
✓                                                         
1. ↓fEPSPa 
(LTD)                             
2. ↓fEPSPa 
>24h (LTD), 
prevented 
(but not 
reversed) by 
AM, present 
in CB1R 
shRNA but 
absent in 
CB1R KO 
NA NA NA ✓                                      
2. LTD via 
activation of 
GluN2B and 
postsynaptic 
endocytosis of 
GluR1/GluR2; 
↓ GluR1 and 
GluR2 
✓                                   
Electrophysiology
, WB analysis 
✓                                 
t-test, 
ANOVA 
Long et al              
(2013) 
✓                
mouse 
(C57BL
/6J)  
✓                          
PND 31 
✓  male ✕ ✓                  
NRG1 WT 
(+/+) and 
HET (+/-) 
✓                                                     
IP, daily, 
for 21 
consecutiv
e days 
from PND 
31, 10 
mg/kg 
NA ✓ ✓                           
Hippocampus, 
Cg, ACo, 
PMCo 
NA NA NA NA ✓                                      
NS, ↑ NMDA 
binding in 
ACo, Cg, and 
Hippocampus 
only in NRG1 
HET (NS 
PMCo)  
✓ 
Autoradiography 
✓                     
ANOVA 
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Spencer et al 
(2013) 
✓                
mouse 
(C57BL
/6J)  
✓                          
PND 32±2 
✓  male ✕ ✓                  
NRG1 WT 
(+/+) and 
HET (+/-) 
✓                                                     
IP, daily, 
for 21 
consecutiv
e days 
from PND 
31, 10 
mg/kg 
NA ✓ ✓                                        
Hippocampus 
NA NA NA NA ✓                                      
NS, ↑ FLOT1 
and APOA1, ↓ 
GPSM2 only in 
NRG1 HET  
✓                                
Mass 
spectrometry,          
WB analysis 
✓                                 
t-test 
Zamberletti et 
al (2014) 
✓                     
rat  
✓                          
PND 28 
✓ 
female 
✕ NA ✓                                                     
IP, twice a 
day, from 
PND 35 to 
PND 45, 
increasing 
doses 
(2.5 mg/kg
, PND 35–
37; 
5 mg/kg, 
PND 38–
41; 
10 mg/kg, 
PND 42–
45) 
NA ✓ ✓                                        
Prefrontal 
cortex, 
Hippocampus 
NA ✓                                            
↓ GAD only at 
PND75 in 
Prefrontal 
cortex (NS 
PND 46 and 60; 
NS 
hippocampus) 
NA NA NA ✓                                
WB analysis, IHC 
for microscopy, In 
vivo MD 
✓                                 
t-test, 
ANOVA 
Rubino et al          
(2015) 
✓                     
rat  
✓                          
PND 28 
✓ 
female 
✕ NA ✓                                                     
1. IP, 
twice a 
day, from 
PND 35 to 
PND 45, 
increasing 
doses 
(2.5 mg/kg
, PND 35–
37; 
5 mg/kg, 
PND 38–
41; 
10 mg/kg, 
PND 42–
45) 
✓                                 
2. AM251 (IP, 
from PND 35 to 
PND 45, or 
from PND 46 to 
PND 60, or 
from PND 60 to 
75, 0.5 mg/kg)  
✓ ✓                                        
Prefrontal 
cortex 
NA NA NA NA ✓                                       
1. ↑ PSD-95 at 
PND 46 and 60 
(NS PND 75), ↑ 
GluN2A at 
PND 60 (NS 
PND 46 and 
75), ↑ GluN2B 
at PND 75 (NS 
PND 46 and 
60), ↑ GluR1 at 
PND 75 (NS 
PND 46 and 
60), NS GluR2        
2. ↑PSD-95 at 
PND 46 and 
60, and ↓at 
PND 75. ↑ 
GluN2A at 
PND 46, 60, 
and 75, ↑ 
GluR2 at PND 
46, 60 (NS 
PND 75), NS 
GluR1 and 
GluN2B  
✓                                
WB analysis 
✓                                 
ANOVA 
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Δ9-THC, delta-9-tetrahydrocannabinol; SD, sprague dawley; PND, postnatal day; PNW, postnatal week; ✕, no information provided; NA, not applicable; CB1R, cannabinoid receptor 1; NRG1, neuregulin 1; WT, wildtype; KO, knockout; HET, heterogeneous; shRNA, short 
hairpin RNA; admin., administration; SR141716A, rimonabant; IP, intraperitoneally; PO, per os; IV, intravenously; PPN, pedunculopontine nucleus; DS, dorsal striatum; NAc, nucleus accumbens; AMYG, amygdala; HTH, hypothalamus; Cg. cingulate cortex; Aco. auditory 
cortex; PMCo, posteromedial cortical amygdaloid nucleus; fEPSPa, field excitatory postsynaptic potentials amplitude; LTP, long term potentiation; EPSCa(f), excitatory postsynaptic current amplitude (frequency);  PPR, paired-pulse ratio; LTD, long term depression; RI, 
rectification index; GAD, glutamic acid decarboxylase; GLDH, glutamate dehydrogenase; neurotr., neurotransmitter; EGL, extracellular glutamate levels; IGL, intracellular glutamate levels; PFC, prefrontal cortex; HPC, hippocampus; GluR1, glutamate receptor 1; GluR2, 
glutamate receptor 2; NMDA, N-methyl-d-aspartate; FLOT-1, flotillin-1; APOA1, apolipoprotein A1; GPSM2, G-protein-signaling modulator 2; PSD-95, postsynaptic density protein 95; HPLC, high-performance liquid chromatography; MD, microdialysis; RT-PCR, real-time 
polymerase chain reaction; WB, western blot; IHC, immunohistochemistry; ANOVA, analysis of variance 
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Table 6.  Summary of animal studies of effect of postnatal in vivo Δ9-THC exposure on glutamate, followed by additional in vitro Δ9-THC exposure  
               
Study Animal 
model 
Stage of 
development  
Sex Weight Genetics Δ9-THC way of 
administration, 
period, dosage  
Other used 
cannabinoids 
(way of 
administration, 
period, dosage) 
Controls Region of 
interest 
Synaptic transmission Neurotr. 
transporters 
Neurotr. 
receptors 
Method Statistics 
Hoffman 
et al              
(2003) 
✓                     
rat  
✓                          
PNW 2-4 
✓  
male 
✕ NA ✓                                                    
1. IP, daily, for 7 
consecutive days, 
10 mg/kg 
✓                                                              
2a. WIN55,212-2 
(IP, daily, for 7 
consecutive days, 
10 mg/kg)                                          
2b. WIN55,212-2 
(in vitro 
application, 1 μM)                                 
3. SR141716A (in 
vitro application, 1 
μM) 
✓ ✓                                   
Nucleus 
accumbens 
✓                                                                                                                       
1. NS LTD (PSs amplitude) after 
5 min at 10 Hz stimulation                                                                         
2a. NS LTD (PSs amplitude) 
after 5 min at 10 Hz stimulation                                                                          
3. prevented LTD after 5 min at 
10 Hz stimulation                                                                           
2b. ↓ N2 component (NS N1 
component),  concentration-
dependent, less effective in 
chronic Δ9-THC treated rats                      
NA NA ✓                                   
Electrophysiology 
✓                     
ANOVA 
Mato et 
al              
(2005) 
✓                
mouse 
(C57BL/6
J) 
✓                          
PNW 4 
✓  
male 
✕ NA ✓                                                    
1a. IP, daily, for 7 
consecutive days, 
3 mg/kg                   
1b. IP, single 
administration, 3 
mg/kg 
✓                                                              
2. CP55,940 (in 
vitro application, 
0.1-100 μM)                                                      
3. SR141716A (in 
vitro application, 1 
μM)               
✓ ✓                                   
Nucleus 
accumbens 
✓                                                                                                                           
1a. NS LTD (fEPSP) after 10 min 
at 13 Hz stimulation; NS eEPSC; 
NS PPR; NS Miniature sEPSC; 
NS basic electrophysiology                                                                                        
1b. ↓ fEPSP (LTD) after 10 min 
at 13 Hz stimulation, but NS 
LTD (fEPSP) after 5 min at 10 
Hz stimulation                                                         
2. ↓ fEPSP, dose response 
dependent, less effective in 
chronic Δ9-THC treated rats                                                                                                    
3. NS fEPSP; prevented LTD 
after 10 min at 13 Hz 
stimulation only in controls (NS 
in chronic Δ9-THC treated rats) 
and animals taken 1 week after 
the last THC injection                              
NA NA ✓                                   
Electrophysiology 
✓                                 
t-test 
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Tonini et 
al             
(2006) 
✓                
mouse 
(C57BL/6
J) 
✓                          
PND 40-50 
✕ ✕ ✓                  
RasGRF1 
WT (+/+) 
and KO               
(-/-) 
✓                                                    
1. SC, twice per 
day, for 4.5 
consecutive days, 
10 mg/kg 
✓                                                              
2a. SR141716A 
(IP, 20 min before 
THC, 3 mg/kg)                                                                   
2b. SR141716A (in 
vitro application, 
10 μM)                                                      
3. CP55,940 (in 
vitro application, 
0.1-20 μM)       
✓ ✓                              
Cerebellum 
✓                                                                                                                             
1. ↑PF-PC EPSCa;↓ PPR, 
prevented by SR in vivo, but 
not reversed by SR in vitro, 
absent in RasGRF1 KO; NS PF-
PC LTD, but ↓ presynaptic PF-
PC LTP, absent in RasGRF1 
KO                                                                                                                          
3. ↓ EPSC, dose response 
dependent, reversed by SR, less 
effective in chronic Δ9-THC 
treated rats, but equally 
effective in RasGRF1 KO    
NA NA ✓                                   
Electrophysiology 
✓                                 
t-test 
Hoffman 
et al              
(2007) 
✓                     
rat 
(Sprague 
Dawley) 
✓                          
PNW 2-4 
✓  
male 
✕ NA ✓                                                    
1. IP, daily, for 7 
consecutive days, 
10 mg/kg                                                            
✓                                                           
2a. AM251 (IP, 
either alone or 30 
min before THC, 2
mg/kg)      2b. 
AM251 (in vitro 
application, 1 μM)                                                        
3. SR141716A (in 
vitro application, 1 
μM)                                  
4. WIN55,212-2 
✓ ✓                                        
Hippocampus 
✓                                                                                                                      
1. ↓fEPSP (↓of HFS and TBS 
LTP), time dependent (effect 
from day 3), partially reversed 
3-14 days after the last THC 
injection; ↓ PPR; ↑ sEPSCa but 
not sEPSCf                                                                                                                    
2a. NS                                                                                                                        
2b. NS                                                                                                                         
3. NS                                                                                                                         
4. ↓fEPSP (↓ LTP), dose-
response dependent, equally 
effective in chronic Δ9-THC 
treated rats                                                                
NA ✓                                                                                                  
1. NS NMDA 
synaptic currents                                                                               
✓                                   
Electrophysiology 
✓
ANOVA 
Chen et 
al              
(2013) 
✓                
mouse 
(C57BL/6
J) 
✓                          
PNW 7-14 
✕ ✕ NA ✓                                                    
1a. IP, daily, for 7 
consecutive days, 
10 mg/kg                                   
1b. In vitro 
application, 3 μM 
NA ✓ ✓                                        
Hippocampus 
✓                                                                                                                      
1a. ↓fEPSP (↓of LTP)                                                                                     
1b. ↑ Miniature sEPSC           
✓
1a. ↓ GLAST and
GLT1, (NS 
EAAC1) 
✓                        
1a. ↓GluR1,
GluN2A, and 
GluN2B total, 
surface, synaptic, 
extrasynaptic  
✓                                                 
Electrophysiology
, IHC for 
microscopy and 
morphometry, WB 
analysis 
✓                                 
t-test, 
ANOVA 
 
Δ9-THC, delta-9-tetrahydrocannabinol; PND, postnatal day; PNW, postnatal week; ✕, no information provided; NA, not applicable; RasGRF1, Ras protein-specific guanine nucleotide-releasing factor; WT, wildtype; KO, knockout; SR141716A, rimonabant;  IP, 
intraperitoneally; SC, subcutaneously; LTD, long term depression; PSs, glutamate-driven population spikes; fEPSP, field excitatory postsynaptic potentials; e(s)EPSCa, evoked (spontaneous) excitatory postsynaptic current amplitude; PPR, paired-pulse ratio;  PF-PC, 
parallel fiber-Purkinje cell; LTP, long term potentiation; HFS, high-frequency stimulation; TBS, θ burst stimulation; neurotr, neurotransmitter; GLT1, glutamate transporter 1; EAAC1, excitatory amino acid carrier 1; GLAST, L-glutamate/L-aspartate transporter; GluR1, 
glutamate receptor 1; GluR2, glutamate receptor 2; NMDA, N-methyl-d-aspartate; WB, western blot; IHC, immunohistochemistry; ANOVA, analysis of variance 
